AI Article Synopsis
- The study explores how the daily variations in D2 receptor density might influence the side effects of antipsychotic drugs, specifically haloperidol, in male schizophrenic patients.
- Examination of 18 hospitalized patients revealed that symptoms like akathisia and dystonia were less severe in the morning and worsened at night, while Parkinsonian symptoms were more prominent in the morning.
- These findings suggest that the time of day affects the severity of extrapyramidal symptoms, indicating that different receptor mechanisms may be at play based on circadian rhythms.
Article Abstract
Despite the fact that the circadian variations in the density of striatal dopaminergic D2 receptors are well documented, there are few reports concerning whether these variations may regulate the extrapyramidal symptoms produced by antipsychotic drugs. To test this hypothesis, we selected 18 male hospitalized schizophrenic subjects, who had been treated for 2 wk with 10 mg haloperidol three times a day. The extrapyramidal symptoms were evaluated 1 h after each haloperidol administration (e.g. 09:00, 14:00 and 19:00 hours). The diurnal profiles of haloperidol-induced extrapyramidal symptoms showed that akathisia and dystonia were milder in the morning and increased in severity during the night. However, Parkinsonian symptoms were more severe during the morning evaluations than during the evening tests. The difference in the diurnal pattern of the haloperidol-induced side-effects, suggests that receptor-related mechanisms with a different circadian profile contribute to the induction of the extrapyramidal symptoms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S1461145703003511 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the Pharmacological and Clinical Features of Lumateperone: A Promising Novel Antipsychotic.
Int J Mol Sci
December 2024
Section of Affective Disorders, Department of Psychiatry, Jagiellonian University Medical College, Kopernika 21a, 31-501 Kraków, Poland.
Lumateperone is a novel antipsychotic recently approved for the treatment of schizophrenia. Its unique pharmacological profile includes modulation of serotonergic, dopaminergic, and glutamatergic neurotransmission, differentiating it from other second-generation antipsychotics. This paper explores the pharmacological features and clinical potential of lumateperone across neuropsychiatric conditions.
View Article and Find Full Text PDFEvaluating Adverse Drug Reactions, Their Reporting Rates and Their Impact on Attitudes Toward Pharmacotherapy Among Female Patients with Schizophrenia: Insights and Implications from a Cross-Sectional Study.
Healthcare (Basel)
December 2024
Department of Pharmacy, University of Split School of Medicine, Soltanska 2A, 21000 Split, Croatia.
Background/objectives: Schizophrenia is a chronic psychiatric disorder usually managed with antipsychotics, which can cause adverse drug reactions (ADRs) that may impact patients' attitudes toward their treatment, as well as treatment adherence. This study aimed to assess the influence of ADRs and other factors on treatment attitudes among female patients with schizophrenia.
Methods: A cross-sectional study was conducted at the Vrapče Psychiatry Clinic with 109 female schizophrenia patients.
Haloperidol dopamine receptor occupancy and antagonism correspond to delirium agitation scores and EPS risk: A PBPK-PD modeling analysis.
J Psychopharmacol
January 2025
Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Background: Delirium is a severe neuropsychiatric disorder associated with increased morbidity and mortality. Numerous precipitating factors and etiologies merge into the pathophysiology of this condition which can be marked by agitation and psychosis. Judicious use of antipsychotic medications such as intravenous haloperidol reduces these symptoms and distress in critically ill individuals.
View Article and Find Full Text PDFEffectiveness and safety of aripiprazole oral solution in the acute treatment of schizophrenia in Chinese patients.
BMC Psychiatry
December 2024
The National Clinical Research Center for Mental Disorders, Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, 100088, China.
Background: This study investigates the effectiveness and safety of aripiprazole oral solution in Chinese patients with schizophrenia.
Methods: This was a multicenter, single-arm phase IV study involving 134 patients in China in the acute stage of schizophrenia from May 2021 to July 2022. The patients received aripiprazole oral solution 10 - 30 mg/d for 12 weeks.
Haloperidol-Induced Catalepsy and Its Correlations with Acetylcholinesterase Activity in Different Brain Structures of Mice.
Neurol Int
December 2024
Natural and Humanities Sciences Center (CCNH), Experimental Morphophysiology Laboratory, Federal University of ABC (UFABC), São Bernardo do Campo 09606-070, Brazil.
Background/objectives: Antipsychotic medicines are used to treat several psychological disorders and some symptoms caused by dementia and schizophrenia. Haloperidol (Hal) is a typical antipsychotic usually used to treat psychosis; however, its use causes motor or extrapyramidal symptoms (EPS) such as catalepsy. Hal blocks the function of presynaptic D2 receptors on cholinergic interneurons, leading to the release of acetylcholine (ACh), which is hydrolyzed by the enzyme acetylcholinesterase (AChE).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!